Long non-coding RNAs and tyrosine kinase-mediated drug resistance in pancreatic cancer

被引：0
作者：
Li, Dangran [1 ,2 ]
Weng, Shiting [1 ,3 ]
Zeng, Kai [1 ]
Xu, Hanmiao [1 ]
Wang, Wenyueyang [1 ]
Shi, Jinsong [1 ]
Chen, Jinghua [1 ]
Chen, Chen [1 ]
机构：
[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Key Lab Carbohydrate Chem & Biotechnol, Minist Educ, Wuxi 214122, Peoples R China
[2] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210029, Peoples R China
[3] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China
来源：
GENE | 2024年 / 895卷
关键词：
LncRNA; MicroRNA; Pancreatic ductal adenocarcinoma; Chemoresistance; Targeted therapy; Tyrosine kinase; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE RESISTANCE; C-MET; FACTOR RECEPTOR; EXPRESSION; PROMOTES; OVEREXPRESSION; SURVIVAL; CHEMORESISTANCE; PROGRESSION;
D O I：
10.1016/j.gene.2023.148007
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Pancreatic cancer (PC) is one of the most malignant tumors with a dismal survival rate, this is primarily due to inevitable chemoresistance. Dysfunctional tyrosine kinases (TKs) and long non-coding RNAs (lncRNAs) affect the drug resistance and prognosis of PC. Here, we summarize the mechanisms by which TKs or lncRNAs mediate drug resistance and other malignant phenotypes. We also discuss that lncRNAs play oncogenic or tumor suppressor roles and different mechanisms including lncRNA-proteins/microRNAs to mediate drug resistance. Furthermore, we highlight that lncRNAs serve as upstream regulators of TKs mediating drug resistance. Finally, we display the clinical significance of TKs (AXL, EGFR, IGF1R, and MET), clinical trials, and lncRNAs (LINC00460, PVT1, HIF1A-AS1). In the future, TKs and lncRNAs may become diagnostic and prognostic biomarkers or drug targets to overcome the drug resistance of PC.
引用
收藏
页数：11
相关论文
共 108 条
  • [1] Long noncoding RNAs (lncRNAs) in pancreatic cancer progression
    Ashrafizaden, Milad
    Rabiee, Navid
    Kumar, Alan Prem
    Sethi, Gautam
    Zarrabi, Ali
    Wang, Yuzhuo
    [J]. DRUG DISCOVERY TODAY, 2022, 27 (08) : 2181 - 2198
  • [2] PhaseIIstudy evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE1)
    Assenat, Eric
    Mineur, Laurent
    Mollevi, Caroline
    Lopez-Crapez, Evelyne
    Lombard-Bohas, Catherine
    Samalin, Emmanuelle
    Portales, Fabienne
    Walter, Thomas
    de Forges, Helene
    Dupuy, Marie
    Boissiere-Michot, Florence
    Ho-Pun-Cheung, Alexandre
    Ychou, Marc
    Mazard, Thibaut
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (03) : 682 - 691
  • [3] Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
    Bergman, AM
    Pinedo, HM
    Peters, GJ
    [J]. DRUG RESISTANCE UPDATES, 2002, 5 (01) : 19 - 33
  • [4] Long Noncoding RNA and Cancer: A New Paradigm
    Bhan, Arunoday
    Soleimani, Milad
    Mandal, Subhrangsu S.
    [J]. CANCER RESEARCH, 2017, 77 (15) : 3965 - 3981
  • [5] Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
    Bianco, Cataldo
    Giovannetti, Elisa
    Ciardiello, Fortunato
    Mey, Valentina
    Nannizzi, Sara
    Tortora, Giampaolo
    Troiani, Teresa
    Pasqualetti, Francesco
    Eckhardt, Gail
    de Liguoro, Mario
    Ricciardi, Simona
    Del Tacca, Mario
    Raben, David
    Cionini, Luca
    Danesi, Romano
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (23) : 7099 - 7107
  • [6] LNCcation: lncRNA localization and function
    Bridges, Mary Catherine
    Daulagala, Amanda C.
    Kourtidis, Antonis
    [J]. JOURNAL OF CELL BIOLOGY, 2021, 220 (02)
  • [7] Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer
    Camblin, Adam J.
    Pace, Emily A.
    Adams, Sharlene
    Curley, Michael D.
    Rimkunas, Victoria
    Nie, Lin
    Tan, Gege
    Bloom, Troy
    Ladevaia, Sergio
    Baum, Jason
    Minx, Charlene
    Czibere, Akos
    Louis, Chrystal U.
    Drummond, Daryl C.
    Nielsen, Ulrik B.
    Schoeberl, Birgit
    Pipas, J. Marc
    Straubinger, Robert M.
    Askoxylakis, Vasileios
    Lugovskoy, Alexey A.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (12) : 2873 - 2885
  • [8] A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
    Cazes, Alex
    Betancourt, Oscar
    Esparza, Edgar
    Mose, Evangeline S.
    Jaquish, Dawn
    Wong, Eric
    Wascher, Alexis A.
    Tiriac, Herve
    Gymnopoulos, Marco
    Lowy, Andrew M.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (07) : 2100 - 2110
  • [9] Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets
    Chang, Katherine
    Karnad, Anand
    Zhao, Shujie
    Freeman, James W.
    [J]. ONCOTARGET, 2015, 6 (06) : 3507 - 3518
  • [10] The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity
    Chekmarev, Jason
    Azad, Mahan Gholam
    Richardson, Des R.
    [J]. CELLS, 2021, 10 (09)
12345678910